The Molecular Genomics Core Facility provides a centralized resource for the molecular analysis of the genome and transcriptome of cells and tissues. Analysis can occur at the level of a single nucleotide, a single molecule, and a single sample or involve multiple nucleotides, multiple molecules, and multiple samples. The laboratory offers single molecule sequencing, PCR-based analysis of genes and transcripts, and microarray based analysis of transcriptomes and genomes. In this era of high content analysis the goal is to economically measure the highest combination of nucleotides, molecules, and samples. As a centralized facility for all levels of assessment the laboratory provides the expertise required to determine the best technology to use for a research objective. The laboratory also provides expertise in the isolation, preservation, and handling of nucleic acids and training in the use of basic bioinformatics software needed to assess experimental data, access web resources, or perform follow-up investigations. Molecular Genomics Core represents the integration of complementary platforms through a single access point. The core merges the Microarray Core and the Molecular Biology Core as submitted at the last renewal. New equipment and services since the last renewal includes: an ABI 7900 Real Time PCR machine, a Agilent Surescan High-resolution DNA microarray scanner, an Xceed Molecular Ziplex microarray system, the lllumina HiScanSQ system, microarray-based for ChlP-on-ChIP experiements, expanded genotyping and mutational analysis options, and implementation of a LIMS system. The Core requests CCSG Support of $264,488, which is 30% of its operational budget. Over 92% of usage is by Moffitt members and peer-reviewed.

Public Health Relevance

The core provides an efficient and essential resource for Moffitt Members to analyze changes in gene/genomes and epigenetie factors. The Molecular Genomics Core has contributed greatly to the scientific investigations occurring at the Cancer Center and contributed to science on a national level.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613447
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$77,188
Indirect Cost
$31,379
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82
Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61
Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7
Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6
Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83
Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1
Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50
Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888

Showing the most recent 10 out of 108 publications